Cargando…
Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients
BACKGROUND/AIMS: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have sh...
Autores principales: | Seo, Da Hea, Cho, Yongin, Lee, Sujin, Park, Seho, Kim, Seung-Il, Park, Byeong Woo, Rhee, Yumie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506747/ https://www.ncbi.nlm.nih.gov/pubmed/28838227 http://dx.doi.org/10.3904/kjim.2016.205 |
Ejemplares similares
-
Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
por: Kim, Wonjin, et al.
Publicado: (2015) -
Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus
por: Cho, Yongin, et al.
Publicado: (2023) -
Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006) -
Presence of Carotid Plaque Is Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Normal Renal Function
por: Seo, Da Hea, et al.
Publicado: (2019) -
Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Ahn, Jee Hyun, et al.
Publicado: (2021)